SCHEMBL5648656

SCHEMBL5648656

CCN(CC)CCCNC(=O)c1ccc(-c2nc3c(C)c(C)c(Br)cc3[nH]2)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.42
TP53 P04637 3/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GLA P06280 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
IGF1R P08069 2/20 0.40
MAPT P10636 2/20 0.40
TSHR P16473 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649826 0.94 GAA (0.43) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5652799 0.91 GAA (0.41) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5653201 0.90 PRMT5 (0.48) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5652439 0.89 HPSE (0.44) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5652552 0.88 HDAC6 (0.44) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5652617 0.87 FLT3 (0.45) KDM4EHSD17B10HPSE
SCHEMBL5648651 0.86 GAA (0.44) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5650407 0.84 APLNR (0.47) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5651923 0.83 PRKD3 (0.45) GAATP53HTTKDM4ESMN1; SMN2
SCHEMBL5650993 0.82 HPSE (0.49) GAATP53HTTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 GAA 4139/4885TP53 4051/4885HTT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.